Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells.
Adult
Animals
Breast Neoplasms
/ blood
CD8-Positive T-Lymphocytes
/ immunology
Cell Line, Tumor
Chemokines
/ metabolism
Denosumab
/ pharmacology
Female
Humans
Immunity
Immunosuppression Therapy
Immunotherapy
Inflammation Mediators
/ metabolism
Lymphocytes, Tumor-Infiltrating
/ immunology
Mice, Inbred C57BL
Middle Aged
Models, Biological
Myeloid Cells
/ immunology
Neoplasm Staging
Neutrophils
/ immunology
RANK Ligand
/ blood
Receptor Activator of Nuclear Factor-kappa B
/ metabolism
Signal Transduction
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
10 12 2020
10 12 2020
Historique:
received:
09
06
2020
accepted:
12
11
2020
entrez:
11
12
2020
pubmed:
12
12
2020
medline:
29
12
2020
Statut:
epublish
Résumé
Most breast cancers exhibit low immune infiltration and are unresponsive to immunotherapy. We hypothesized that inhibition of the receptor activator of nuclear factor-κB (RANK) signaling pathway may enhance immune activation. Here we report that loss of RANK signaling in mouse tumor cells increases leukocytes, lymphocytes, and CD8
Identifiants
pubmed: 33303745
doi: 10.1038/s41467-020-20138-8
pii: 10.1038/s41467-020-20138-8
pmc: PMC7728758
doi:
Substances chimiques
Chemokines
0
Inflammation Mediators
0
RANK Ligand
0
Receptor Activator of Nuclear Factor-kappa B
0
Denosumab
4EQZ6YO2HI
Banques de données
ClinicalTrials.gov
['NCT01864798']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6335Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Références
J Immunol. 2003 Mar 15;170(6):3233-42
pubmed: 12626582
Inflammation. 2008 Feb;31(1):36-46
pubmed: 17874178
BMC Bioinformatics. 2009 May 27;10:161
pubmed: 19473525
FEBS J. 2016 Jun;283(11):2018-33
pubmed: 26749530
Front Immunol. 2014 Oct 20;5:511
pubmed: 25368616
Breast Cancer Res. 2007;9(4):212
pubmed: 17705880
Breast Cancer. 2015 Mar;22(2):185-91
pubmed: 23645542
Nat Rev Clin Oncol. 2016 Apr;13(4):228-41
pubmed: 26667975
Nat Med. 2016 Aug;22(8):933-9
pubmed: 27322743
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Genes Immun. 2013 Jul-Aug;14(5):336-45
pubmed: 23698708
Nat Commun. 2017 Feb 01;8:14381
pubmed: 28146145
J Leukoc Biol. 2010 Nov;88(5):877-84
pubmed: 20573802
Cell. 2000 Sep 29;103(1):41-50
pubmed: 11051546
Appl Immunohistochem Mol Morphol. 2017 May/Jun;25(5):299-307
pubmed: 28248730
BMC Cancer. 2014 Jul 30;14:550
pubmed: 25073969
Nature. 2010 Jun 10;465(7299):803-7
pubmed: 20445538
Oncoimmunology. 2016 Dec 14;6(1):e1257452
pubmed: 28197375
Annu Rev Immunol. 2014;32:659-702
pubmed: 24655300
Ann Oncol. 2015 Aug;26(8):1533-46
pubmed: 25939896
Cancer Res. 2012 Jun 1;72(11):2879-88
pubmed: 22496457
Cancer Res. 2016 Oct 1;76(19):5857-5869
pubmed: 27480274
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
J Clin Oncol. 2011 Jun 10;29(17):2342-9
pubmed: 21555689
Oncoimmunology. 2017 Aug 16;6(11):e1356965
pubmed: 29147615
Nature. 1997 Nov 13;390(6656):175-9
pubmed: 9367155
Sci Transl Med. 2012 Mar 28;4(127):127ra37
pubmed: 22461641
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Genome Biol. 2014;15(12):550
pubmed: 25516281
J Immunol. 2008 Oct 15;181(8):5791-802
pubmed: 18832739
Nature. 2010 Jun 10;465(7299):798-802
pubmed: 20383121
Am J Clin Oncol. 2016 Feb;39(1):98-106
pubmed: 26558876
Oncoimmunology. 2018 Feb 14;7(6):e1431088
pubmed: 29872559
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
J Thorac Dis. 2018 Feb;10(Suppl 3):S404-S411
pubmed: 29593886
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Breast Cancer Res Treat. 2014 Jun;145(2):307-15
pubmed: 24737168
Breast Cancer Res. 2016 Apr 01;18(1):39
pubmed: 27036195
Lancet Oncol. 2018 Jan;19(1):3-5
pubmed: 29233560
Nature. 2009 Nov 26;462(7272):505-9
pubmed: 19940926
Nature. 2010 Nov 4;468(7320):98-102
pubmed: 20881962
Lancet Oncol. 2020 Jan;21(1):60-72
pubmed: 31806543
FEBS J. 2018 Dec;285(23):4316-4342
pubmed: 29851227
Nat Med. 2015 Jul;21(7):677-87
pubmed: 26121197
Breast Cancer Res. 2015 Feb 21;17:24
pubmed: 25849336
Cancer Cell. 2009 Sep 8;16(3):183-94
pubmed: 19732719
Lancet Oncol. 2019 Mar;20(3):339-351
pubmed: 30795951
Mol Cell Biol. 2007 Feb;27(4):1442-54
pubmed: 17145767
Clin Cancer Res. 2017 Oct 1;23(19):5789-5801
pubmed: 28634284
Transgenic Res. 1999 Aug;8(4):265-77
pubmed: 10621974
Nature. 2010 Nov 4;468(7320):103-7
pubmed: 20881963
J Biol Chem. 2004 Jul 16;279(29):30202-9
pubmed: 15145935
Mol Cell Biol. 1992 Mar;12(3):954-61
pubmed: 1312220
J Leukoc Biol. 2005 Jul;78(1):167-77
pubmed: 15831559
Sci Transl Med. 2013 Aug 28;5(200):200ra116
pubmed: 23986400
Cell Res. 2016 Jul;26(7):761-74
pubmed: 27241552
Nat Rev Cancer. 2016 Jul;16(7):431-46
pubmed: 27282249
Immunity. 2002 Feb;16(2):183-91
pubmed: 11869680
J Immunol. 2002 Apr 1;168(7):3195-204
pubmed: 11907072
Genes Dev. 1999 Sep 15;13(18):2412-24
pubmed: 10500098
JAMA Oncol. 2019 Apr 11;:
pubmed: 30973611